06.19.2023 - By PeerVoice
Visit https://www.peervoice.com/RTV860 to view the entire programme with slides. After completing “Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations”, participants will be able to: Compare current and emerging fibroblast growth factor receptor (FGFR) inhibitors based on pharmacology, study designs and outcomes, and place in therapy; Identify specific patient-level characteristics, comorbidities, and presentations which may impact treatment selection in cholangiocarcinoma (CCA); and Design individualised regimens for specific patients with CCA and FGFR alterations.